All Companies
🇺🇸
Turn Biotechnologies
PrivatemRNA epigenetic reprogramming
Turn Biotechnologies has developed ERA (Epigenetic Reprogramming of Aging), an mRNA-based platform that delivers transient Yamanaka factors to reverse cellular aging. Their approach avoids the cancer risks of continuous reprogramming.
Founded2018
HQMountain View, CA
CEOVittorio Sebastiano
StatusPrivate
Total Funding$60M
Pipeline
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| ERA Osteoarthritis | Osteoarthritis | Preclinical | mRNA Reprogramming |
| ERA Dermatology | Skin aging | Preclinical | mRNA Reprogramming |
Key People
Vittorio SebastianoCEO & Co-founder